Navigation Links
Amgen Completes Acquisition of BioVex
Date:3/4/2011

lationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 The Wolf Administration today ... Pennsylvania State Police and local ... naloxone. Heroin and opioid overdose are the ... , killing more individuals than those involved in ... died from a drug overdose. " ...
(Date:8/31/2015)... 2015  The departments of Drug and Alcohol Programs ... Concept 90 to raise awareness for International Overdose Awareness ... Pennsylvania and help more Pennsylvanians with ... through the Building Bridges to Recovery initiative. ... day to a disease that is fully treatable, if ...
(Date:8/31/2015)... -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX ), a late-stage ... Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical ... investor conferences in September. , ... LLC Emerging Growth Conference in New ... President & Chief Executive Officer, will present a corporate ...
Breaking Medicine Technology:Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... First-in-Class Biologic Treatment Option Now Available for ... Use in Pediatric Patients with JIA(1,2) -, PRINCETON, ... ) today announced that the U.S. Food and Drug,Administration (FDA) ... patients six years and older with moderately to,severely active polyarticular ...
... Model Created Using Piecewise Smooth Subdivision Surface Provides Both ... of Fallot Patients, SEATTLE, April 8, 2008 ... and volumetric insights,that help cardiologists diagnose and treat patients ... in the American Journal,Cardiology (2008; Vol. 101, Issue 1, ...
Cached Medicine Technology:U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 2Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 3
(Date:9/1/2015)... ... September 01, 2015 , ... e-Spirit Inc., a leading supplier ... FirstSpirit Content Management System with new capabilities and enhancements designed to support the ... will be well on their way to achieving digital transformation with less time ...
(Date:9/1/2015)... ... September 01, 2015 , ... Zecurion, a leading developer of data loss ... version of endpoint DLP developed specifically for Mac OS. , In June 2015, the ... IT and information security professionals had participated. The beta test done by the developer ...
(Date:9/1/2015)... ... September 01, 2015 , ... The FSH Society , the ... muscular dystrophy (FSHD), will be the beneficiary of a collection of fundraising events this ... raise awareness of the FSH Society and further FSHD research. , The ...
(Date:9/1/2015)... ... 01, 2015 , ... Agriculture innovation, urban farming, local food access, and sourcing ... discussed at Seedstock’s 4th Annual Sustainable Agriculture Conference : “Innovation and the Rise ... In addition to keynotes Pierre Sleiman, founder and CEO of Go Green Agriculture, and ...
(Date:9/1/2015)... ... 2015 , ... METTLER TOLEDO has announced an upcoming webinar ... , featuring Ed Szczesny (Quality Assurance, Rhodes Pharmaceuticals) as guest presenter. This webinar ... , Calibration, qualification, and the appropriate level of routine testing for laboratory instruments ...
Breaking Medicine News(10 mins):Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Zecurion Announces Endpoint Security for Mac 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 2Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 4Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 5Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2
... Learning, NEW YORK, Feb. 7 Immediate ... quality medical care and can mean the,difference between ... Health,Record (EHR) systems, used by physicians, offices in ... those critical moments.,McGraw-Hill Higher Education has published a ...
... offer quality medical care with help from ... local hospital ... first co-branded in-store clinics will open in Atlanta,Little Rock and Dallas ... which is expected to open in April -- will be connected ...
... aftermarket insoles will also be introduced, AMHERST, Mass., ... insoles, has partnered with Merrell to incorporate its,proprietary insoles ... will expand the number of shoes OrthoLite insoles throughout ... performance by millions of,pairs., In addition, Merrell will ...
... Markets -, LONG BEACH, N.Y., Feb. 7 ... third largest long-term care,pharmacy, today announced that it has ... four of its institutional pharmacies,which serve a variety of ... as well as parts of New Jersey, upstate New ...
... HCA today announced financial,and operating results for the fourth quarter and year ended ... Revenues increased 6.1 percent to $6.883 billion. -- ... prior year. -- ... in the prior year. ...
... to Key 2008 Presidential Campaign ... Issue, ... U.S. companies, large and small, in promoting the fact,that they hire and employ ... to market, both online and,offline, the fact that they exclusively employ legal workers., ...
Cached Medicine News:Health News:McGraw-Hill Higher Education Publishes Text on Innovative Electronic Health Records System 2Health News:'The Clinic at Wal-Mart' to Open in Atlanta, Little Rock and Dallas Supercenters 2Health News:'The Clinic at Wal-Mart' to Open in Atlanta, Little Rock and Dallas Supercenters 3Health News:'The Clinic at Wal-Mart' to Open in Atlanta, Little Rock and Dallas Supercenters 4Health News:Merrell Updates Performance Line with the Launch of OrthoLite Insoles 2Health News:Chem Rx Surpasses 65,000 Residents Served 2Health News:HCA Reports Fourth Quarter - Year End 2007 Results 2Health News:HCA Reports Fourth Quarter - Year End 2007 Results 3Health News:HCA Reports Fourth Quarter - Year End 2007 Results 4Health News:HCA Reports Fourth Quarter - Year End 2007 Results 5Health News:HCA Reports Fourth Quarter - Year End 2007 Results 6Health News:HCA Reports Fourth Quarter - Year End 2007 Results 7Health News:HCA Reports Fourth Quarter - Year End 2007 Results 8Health News:HCA Reports Fourth Quarter - Year End 2007 Results 9Health News:HCA Reports Fourth Quarter - Year End 2007 Results 10Health News:HCA Reports Fourth Quarter - Year End 2007 Results 11Health News:HCA Reports Fourth Quarter - Year End 2007 Results 12Health News:HCA Reports Fourth Quarter - Year End 2007 Results 13Health News:HCA Reports Fourth Quarter - Year End 2007 Results 14Health News:HCA Reports Fourth Quarter - Year End 2007 Results 15Health News:Legal Employer Provides Companies with Competitive Edge by Assuring Consumers that Workers are Legally Documented 2
Complete Blink-N-Clean lens drops cleans and clears lenses in a blink. It is a unique blend of gentle to the eye ingredients that conveniently cleans, clears and keeps lenses feeling comfortable thro...
... preservative free lubricating and rewetting ... eyes while you're wearing soft ... free formula is ideal for ... to preservatives and for frequent ...
Saline Solution to rinse and store soft contact lenses and for heat disinfection....
Sensitive Eyes Plus Saline Solution to rinse soft contact lenses The unique, gentle, pH-balanced formula contains potassium, an ingredient found in tears....
Medicine Products: